Expert Webinar Explores Pressing Questions About Biosorbable Stent Technology
Executive Summary
Boston Scientific and inVentive Health recently sponsored a webinar with four internationally well-known experts on coronary stent technology to discuss the pros and cons of new bioabsorbable polymer stent technologies – both the fully resorbable stents and metal drug-eluting stents with a bioresorbable polymer. Here's a summary of the discussion. Medtech Insight is also providing a complete transcript of the event.
You may also be interested in...
FDA Approves Boston Scientific’s SYNERGY BP Stent For High Bleeding Risk Patients
The bioabsorbable polymer-coated, sirolimus-eluting stent is the first drug-eluting stent approved for this population.
Abbott's Absorb GT1 Is First FDA-Approved Absorbable Coronary Stent
Following the near-unanimous advice of its advisory panel, the US FDA approved Abbott Laboratories’ Absorb GT1 everolimus-eluting biodegradable poly(L-lactide) scaffold, making it the first bioresorbable coronary stent commercially available in the US.
Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.